ENTOS
LIVE

Serial Number

97590573

Owner

ENTOS PHARMACEUTICALS INC.

Attorney

Theodore R. Remaklus

Filing Date

Sep 14, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ENTOS Trademark

Serial Number: 97590573

ENTOS is a trademark filed by ENTOS PHARMACEUTICALS INC. on September 14, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently pending registration.

Owner Contact Info

ENTOS PHARMACEUTICALS INC. (9 trademarks)

10230 JASPER AVENUE, UNIT 4550
EDMONTON, AB T5J4P6 , CA

Entity Type: 03

Trademark Details

Filing Date

September 14, 2022

Registration Date

Not Registered

Published for Opposition

May 7, 2024

Goods & Services

Pharmaceutical and medicinal preparations and substances, namely, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems, namely, the lung in the name of pneumonia, kidneys in the name of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic bone diseases; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely, Crohn's and ulcerative colitis, fatty liver disease, endometriosis, arthritis, autoimmune diseases and disorders, hypoglycemia, gout, osteoarthritis, anemia, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare inflammatory diseases, rare cardiovascular diseases, rare kidney diseases, rare bone diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare bone diseases; cell culture media for cultivating human, animal, plant or microorganism cells for use in the biotechnological industry

Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection

Nucleic acid sequencers for scientific purposes

Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for laboratory use for use in the biotechnological industry; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 30, 2025 EXRA
SOU EXTENSION 3 GRANTED
Dec 30, 2025 EX3G
SOU TEAS EXTENSION RECEIVED
Dec 29, 2025 EEXT
SOU EXTENSION 3 FILED
Dec 28, 2025 EXT3
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
CORRECTED NOA E-MAILED
Sep 5, 2025 NOAC
SOU EXTENSION 2 GRANTED
Sep 5, 2025 EX2G
DIVISIONAL PROCESSING COMPLETE
Sep 5, 2025 DPCC
DIVISIONAL REQUEST RECEIVED
Jun 30, 2025 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Jun 30, 2025 ERTD
SOU TEAS EXTENSION RECEIVED
Jun 30, 2025 EEXT
SOU EXTENSION 2 FILED
Jun 29, 2025 EXT2
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 7, 2025 EXRA
SOU EXTENSION 1 GRANTED
Mar 7, 2025 EX1G
SOU EXTENSION 1 FILED
Dec 30, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 30, 2024 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 7, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 7, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 7, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 7, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 7, 2024 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 2, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 7, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 7, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 17, 2024 NONP
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Mar 28, 2024 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 22, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 12, 2024 XAEC
ASSIGNED TO LIE
Mar 11, 2024 ALIE
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 11, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 11, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 11, 2024 CNEA
DIVISIONAL PROCESSING COMPLETE
Mar 8, 2024 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 6, 2024 AITU
DIVISIONAL REQUEST RECEIVED
Nov 16, 2023 DRRR
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 16, 2023 TROA
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Nov 16, 2023 AMPX
TEAS VOLUNTARY AMENDMENT RECEIVED
Nov 16, 2023 PARI
TEAS REQUEST TO DIVIDE RECEIVED
Nov 16, 2023 ERTD
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Sep 27, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Sep 27, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 27, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 27, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 27, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 26, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 29, 2022 NWOS
NEW APPLICATION ENTERED
Sep 17, 2022 NWAP